相关实验视频

Updated: Jan 12, 2026

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

ALS - Motor Neuron Disease: Mechanism and Development of New Therapies

Published on: July 29, 2007

针对运动神经元疾病 (MND) 的指导方针:范围审查

Cindy Stern¹, Ines Semendric^1,2, Nipun Shrestha¹

¹Health Evidence Synthesis, Recommendations and Impact (HESRI), School of Public Health, Faculty of Health and Medical Sciences, The University of Adelaide, Adelaide, Australia.

Neurodegenerative disease management

|November 3, 2025

概括

现有的运动神经元疾病 (MND) 准则缺乏澳大利亚的背景和高质量的证据. 需要一个全面的,基于证据的MND指导方针来改善对患者和家人的护理.

科学领域:

神经退行性疾病神经退行性疾病
卫生政策卫生政策
基于证据的实践.

背景情况:

运动神经元疾病 (MND) 是一种严重的神经退行性疾病,影响患者,家庭和护理人员.
基于证据的护理对于改善MND的结果至关重要.
现有的指导方针是有限的,没有专门为澳大利亚环境而开发的.

研究的目的:

确定现有的运动神经元疾病 (MND) 的健康和社会护理指南.
评估当前MND指南的质量和范围.
为澳大利亚制定新的指导方针提供信息.

主要方法:

使用乔安娜·布里格斯研究所 (JBI) 方法进行了范围审查.
包括针对MND患者,基因携带者,家庭成员或护理人员的健康和社会护理指南.
数据被提取并进行描述性分析,并对准则问题进行定性内容分析.

主要成果:

包含了42条指南,解决了133个问题,主要集中在症状管理上.
大多数指南是由专业机构制作的,很少有人使用GRADE方法或系统审查.
只有七条指南评估了偏差风险,没有专门为澳大利亚制定指南.

结论:

对于运动神经元疾病 (MND) 的高质量,基于证据的指导方针存在重大差距.
需要使用最佳实践方法制定一个全面的MND指导方针,特别是针对澳大利亚的情况.
改进的指导方针可以支持为MND患者及其支持网络提供基于证据的护理.

关键词:

卢·格里格的疾病是卢·格里格的疾病.运动神经元疾病运动神经元疾病骨髓缩侧面硬化症 (ALS) 是一种准则准则准则神经退行性疾病的神经退行性疾病

更多相关视频

Electrophysiological Motor Unit Number Estimation MUNE Measuring Compound Muscle Action Potential CMAP in Mouse Hindlimb Muscles

Electrophysiological Motor Unit Number Estimation MUNE Measuring Compound Muscle Action Potential CMAP in Mouse Hindlimb Muscles

Published on: September 25, 2015

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

相关概念视频

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...